IADR Abstract Archives
Salivary Interleukin Levels in Patients with Sjogren's Syndrome.
Objectives: To determine salivary levels of interleukin 4 (IL4), 5 (IL5) and 6 (IL6) in subjects with primary Sjögren’s Syndrome (pSS) and to compare them to a healthy control group (HC).
Methods: A Case-control study was conducted. Patients with pSS were recruited from the postgraduate programme of Oral Medicine of the School of Dentistry at Complutense University of Madrid. All pSS patients were diagnosed according to the European-American Consensus of 2002 criteria. HC patients were matched in age and sex to the pSS group. All patients were recruited from December 2015 to March 2018.
Stimulated whole saliva was used to detect ILs levels. Levels of ILs were measured using high-sensitivity multiplex map human immunoassays (Millipore® corporation, Cat. # HSTCMAG-28SK, Billerica, MA, USA) through the Luminex-200 System and the XY platform (Luminex® Corporation, Oosterhout, the Netherlands). The obtained results were analyzed with xPonent® software and were expressed as picograms per milliliter (pg/ml). The detection limits were 1.24 pg/ml, 0.46 pg/ml and 0.11 pg/ml for IL4, IL5 and IL6, respectively.
Results: Thirty-six patients with pSS and 35 HCs were included (all women, 56.58 ± 12.35 years and 54.40 ± 9.16 years, respectively). IL4 and IL5 were not detectable in any group. IL6 was statistically higher in pSS patients than HC (9.73 ± 23.45 vs 0.93 ± 2.70, p = 0.0001). IL6 was statistically higher in pSS patients who had positive salivary gland biopsy (10.83 ± 30.41 vs 0.83 ± 30.41, p = 0.04) and a decrease in unstimulated whole saliva flow (19.11 ± 34.07 vs 3.02 ± 6.01, p = 0.02).
Conclusions: The detection of IL6 in saliva is a non-invasive test that may be a useful biomarker to diagnose and monitor the progression of patients with pSS.
Methods: A Case-control study was conducted. Patients with pSS were recruited from the postgraduate programme of Oral Medicine of the School of Dentistry at Complutense University of Madrid. All pSS patients were diagnosed according to the European-American Consensus of 2002 criteria. HC patients were matched in age and sex to the pSS group. All patients were recruited from December 2015 to March 2018.
Stimulated whole saliva was used to detect ILs levels. Levels of ILs were measured using high-sensitivity multiplex map human immunoassays (Millipore® corporation, Cat. # HSTCMAG-28SK, Billerica, MA, USA) through the Luminex-200 System and the XY platform (Luminex® Corporation, Oosterhout, the Netherlands). The obtained results were analyzed with xPonent® software and were expressed as picograms per milliliter (pg/ml). The detection limits were 1.24 pg/ml, 0.46 pg/ml and 0.11 pg/ml for IL4, IL5 and IL6, respectively.
Results: Thirty-six patients with pSS and 35 HCs were included (all women, 56.58 ± 12.35 years and 54.40 ± 9.16 years, respectively). IL4 and IL5 were not detectable in any group. IL6 was statistically higher in pSS patients than HC (9.73 ± 23.45 vs 0.93 ± 2.70, p = 0.0001). IL6 was statistically higher in pSS patients who had positive salivary gland biopsy (10.83 ± 30.41 vs 0.83 ± 30.41, p = 0.04) and a decrease in unstimulated whole saliva flow (19.11 ± 34.07 vs 3.02 ± 6.01, p = 0.02).
Conclusions: The detection of IL6 in saliva is a non-invasive test that may be a useful biomarker to diagnose and monitor the progression of patients with pSS.